是否无菌：是
本产品通过专属原料筛选、多级深度澄清、酶活控除、三重纳米除菌、昆虫细胞特异性批次筛选五大核心工序，在保留促增殖营养的前提下，剔除抑制昆虫细胞生长的干扰杂质，打造适配昆虫细胞表达系统专用特级胎牛血清。
全流程标准化生产工艺
1.源头原料定向筛选工序（专属前置质控）
-疫区管控采血：仅选用非疫区健康6–8月龄胎牛，无菌心脏穿刺密闭采血，屠宰后30min内低温封存，全程2–8℃冷链，严控溶血，血红蛋白初始值严格限定<100mg/L，减少血红素对昆虫细胞氧化损伤。
-批次预混初筛：初制特级胎牛血清低温均质混合，完成首轮理化筛查；淘汰高磷脂、高游离蛋白酶、高内毒素原料批次，仅保留适配昆虫细胞代谢特征的原料进入精制。
-低温自然凝血分离：4℃静置2–4h充分凝血，3000rpm低温一级离心分离特级初制胎牛血清，减少红细胞破碎释放水解酶，降低核酸酶、蛋白酶本底，避免昆虫细胞重组蛋白降解。
2.多级深度澄清除杂核心工序（昆虫细胞专属精制段）
-梯度二次高速离心澄清：粗血清4500rpm低温长时离心，分层去除脂蛋白颗粒、纤维蛋白微絮、细胞碎片、脂类沉淀物，大幅降低血清低温析出沉淀概率；常规血清仅单次离心，易产生磷酸钙、脂质沉淀堵塞培养瓶滤器，干扰昆虫细胞贴壁与悬浮培养。
-低温酶活钝化处理：全程≤4℃低温精制，规避升温激活内源水解酶；配套专属吸附过滤介质，吸附游离DNase、RNase、蛋白酶，消除昆虫细胞上清目的蛋白、重组核酸降解风险，保障杆状病毒复制与外源蛋白稳定表达。
-噬菌体专项剔除过滤：增加噬菌体截留滤段，全程管控噬菌体阴性；噬菌体可侵染昆虫细胞、裂解宿主，是杆状病毒表达实验常见隐性污染源，通用血清无该专项处理。
3.三重0.1μm无菌纳米过滤除菌
采用0.1μm终端除菌过滤，C级洁净区密闭管路连续生产，逐级截留细菌、真菌、支原体、微囊泡微粒、蛋白聚合物，实现无菌无杂菌状态；较普通两级过滤，杂质截留效率提升一个数量级，适配长期悬浮昆虫细胞大规模发酵培养。
4.无菌分装与低温锁活
过滤合格血清在A级无菌分装线灌装密封，灌装后快速梯度降温：4℃预冷→-20℃速冻锁存，避免温差骤变引发蛋白变性、脂质析出，完整保留促昆虫细胞增殖的生长因子、黏附蛋白、微量元素。
5.昆虫细胞特异性功能筛选放行（差异化关键工序）
所有半成品必须完成昆虫细胞增殖验证方可放行，区别于仅做哺乳动物细胞测试的普通血清：平行测试Sf9、HighFive两种主流昆虫细胞株；检测细胞倍增时间、最大细胞密度、细胞活率维持时长；杆状病毒包装验证：对比病毒滴度、重组蛋白表达水平；淘汰抑制细胞生长、降低病毒表达量的批次，保证每一批血清对昆虫细胞适配性稳定。
本工艺核心差异化优势
1.低沉淀体系，适配悬浮昆虫细胞：多级除脂、除纤维蛋白工艺，低温培养无大量白色沉淀，不干扰镜检、不堵塞生物反应器滤膜，适配摇瓶、生物发酵罐大规模昆虫细胞培养。
3.低水解酶本底，保护重组产物：专项控除核酸酶、蛋白酶，大幅减少杆状病毒基因组降解、目的蛋白水解，提升蛋白纯化回收率。
4.无噬菌体风险，病毒表达稳定：增设噬菌体截留工序，杜绝昆虫细胞隐性裂解污染，保证杆状病毒滴度批次稳定。
5.超低内毒素，降低细胞凋亡：严格原料筛选+多级吸附除热原，低内毒素环境减少昆虫细胞应激凋亡，延长高密度培养周期。
6.专属细胞筛选，批次差异极小：每批均经过双株昆虫细胞功能验证，规避通用血清批次波动导致的蛋白表达量不稳定问题。
使用建议
1.融化规范：将冻存血清优先置于4℃冰箱缓慢过夜解冻，期间每2–3小时轻柔颠倒混匀；完全解冻后37℃短时复温即可使用。严禁室温快速解冻、高温水浴解冻、反复冻融。
2.培养体系配比：常规推荐Grace/TC-100基础培养基+10%本品；高密度悬浮培养可调至8%–12%。
3.体系适配性：无需二次热处理、无需二次过滤，可直接配制培养基；禁止热灭活处理。
4.培养环境：适配27℃恒温、无CO₂常规培养体系。
5.传代与换液：悬浮培养建议每日监测密度与活率；杆状病毒感染前更换新鲜培养基可显著提升滴度与表达量；批次更换无需驯化，可直接替换。
免责声明
本产品仅用于科研或工业用途，不适用于临床治疗。用户需根据自身实验体系验证血清适用性，生产方不承担因操作不当导致的实验结果偏差责任。
This product is developed through five core processes—exclusive raw material screening, multi-stage deep clarification, enzymatic activity control, triple nano-filtration sterilization, and insect cell-specific batch screening. While retaining proliferation-promoting nutrients, it removes interfering impurities that inhibit insect cell growth, delivering a premium fetal bovine serum specially tailored for insect cell expression systems.
Full-Process Standardized Production Workflow
1. Source Material Targeted Screening (Exclusive Pre-Processing Quality Control)
Epidemic-controlled blood collection: Only healthy 6–8 month-old fetal calves from non-epidemic regions are selected. Blood is collected aseptically via closed cardiac puncture and cryopreserved within 30 minutes post-slaughter, with a full cold chain maintained at 2–8°C. Hemolysis is strictly controlled, with initial hemoglobin levels rigorously limited to <100 mg/L to minimize hemin-induced oxidative damage to insect cells.
Batch pre-blending and preliminary screening: Crude premium fetal bovine serum is homogenized at low temperature for initial physicochemical screening. Batches with high phospholipid, high free protease, or high endotoxin content are eliminated; only those compatible with insect cell metabolic characteristics proceed to refining.
Low-temperature natural clotting and separation: After complete clotting at 4°C for 2–4 hours, the serum is separated via primary low-temperature centrifugation at 3000 rpm. This minimizes erythrocyte rupture and the release of hydrolases, reducing background nuclease and protease activities, thereby preventing degradation of recombinant proteins in insect cells.
2. Multi-Stage Deep Clarification and Impurity Removal (Insect Cell-Specific Refining)
Gradient secondary high-speed centrifugation clarification: Crude serum undergoes prolonged low-temperature centrifugation at 4500 rpm to remove lipoprotein particles, fibrin micro-aggregates, cell debris, and lipid precipitates, significantly reducing the probability of cold-induced precipitation. Conventional sera, which undergo only single centrifugation, tend to produce calcium phosphate and lipid precipitates that clog culture flask filters and interfere with insect cell adherence and suspension culture.
Low-temperature enzymatic activity inactivation: The entire refining process is carried out at ≤4°C to prevent temperature-induced activation of endogenous hydrolases. Dedicated adsorptive filtration media are used to adsorb free DNase, RNase, and proteases, eliminating the risk of degradation of target proteins and recombinant nucleic acids in the supernatant, thereby ensuring stable baculovirus replication and exogenous protein expression.
Bacteriophage-specific removal filtration: An additional bacteriophage-retention filtration step is incorporated to ensure the entire process remains bacteriophage-negative. Bacteriophages can infect and lyse insect host cells, representing a common occult contaminant in baculovirus expression experiments—an issue not addressed by conventional sera.
3. Triple 0.1 μm Sterile Nano-Filtration
Terminal sterilization is achieved using 0.1 μm filtration in a closed-pipe continuous production system within a Grade C clean zone. This step sequentially retains bacteria, fungi, mycoplasmas, microvesicles, and protein aggregates, ensuring a sterile and contaminant-free product. Compared to standard two-stage filtration, impurity retention efficiency is improved by an order of magnitude, making it suitable for long-term large-scale fermentation of suspension-adapted insect cells.
4. Aseptic Filling and Low-Temperature Activity Preservation
Qualified serum is filled and sealed in a Grade A aseptic filling line, followed by rapid gradient cooling: pre-chilling at 4°C → flash-freezing at –20°C for cryopreservation. This avoids abrupt temperature fluctuations that could cause protein denaturation or lipid precipitation, preserving growth factors, adhesion proteins, and trace elements that promote insect cell proliferation.
5. Insect Cell-Specific Functional Screening and Release (Differentiating Critical Step)
All semi-finished products must pass insect cell proliferation validation before release, in contrast to conventional sera tested only on mammalian cells. Two mainstream insect cell lines, Sf9 and HighFive, are tested in parallel for cell doubling time, maximum cell density, and viability maintenance duration. Baculovirus packaging validation includes comparison of viral titers and recombinant protein expression levels. Batches that inhibit cell growth or reduce viral expression are discarded, ensuring consistent compatibility of each serum batch with insect cells.
Core Differentiating Advantages of This Process
1.Low-precipitation system, adapted to suspension insect cells: Multi-stage lipid and fibrin removal ensures minimal white precipitate during low-temperature culture, without interfering with microscopy or clogging bioreactor membranes. It is compatible with shake flasks and large-scale insect cell culture in fermenters.
2.Low hydrolase background, protecting recombinant products: Targeted removal of nucleases and proteases significantly reduces baculovirus genome degradation and target protein hydrolysis, enhancing protein purification recovery yields.
3.Bacteriophage-free, stable viral expression: The additional bacteriophage-retention step eliminates occult insect cell lysis contamination, ensuring batch-to-batch stability of baculovirus titers.
4.Ultra-low endotoxin, reducing apoptosis: Strict raw material screening combined with multi-stage adsorption pyrogen removal creates a low-endotoxin environment that minimizes insect cell stress-induced apoptosis, extending high-density culture periods.
5.Dedicated cell-line screening, minimal batch-to-batch variation: Each batch is functionally validated on two insect cell lines, avoiding the protein expression instability commonly caused by batch fluctuations in conventional sera.
Usage Recommendations
1.Thawing protocol: Frozen serum should be thawed slowly overnight at 4°C, with gentle inversion mixing every 2–3 hours to ensure uniform distribution of components. After complete thawing, it may be briefly warmed to 37°C before use. Rapid thawing at room temperature, high-temperature water-bath thawing, and repeated freeze-thaw cycles are strictly prohibited.
2.Culture medium formulation: For routine insect cell culture, a recommended formulation is Grace's/TC-100 basal medium supplemented with 10% of this serum. For high-density suspension culture and large-scale protein expression, the concentration may be adjusted to 8%–12% depending on cell status, to balance cell viability and expression efficiency.
3.System compatibility: This product has been specifically processed to contain low levels of DNase, RNase, and proteases, and is bacteriophage-free. It requires no secondary heat inactivation or secondary filtration and can be used directly in medium preparation. Heat inactivation is forbidden, as high temperatures will destroy the specialized active components adapted for insect cells, leading to apoptosis and reduced viral packaging efficiency.
4.Culture conditions: The serum is compatible with standard insect cell culture conditions at 27°C without CO₂ supplementation. Its low-impurity profile effectively prevents membrane clogging and system turbidity during large-scale culture in suspension shake flasks or bioreactors, supporting long-term high-density fermentation.
5.Subculture and medium exchange recommendations: Given the short doubling time and rapid metabolism of insect cells in suspension culture, daily monitoring of cell density and viability is recommended, with timely subculture and medium exchange. Replacing with fresh medium before baculovirus infection significantly improves viral titers and recombinant protein yields. When switching between serum batches, no cell acclimatization is required due to excellent batch-to-batch consistency—direct replacement is feasible.
Disclaimer
This product is intended for research or industrial use only and is not suitable for clinical therapeutic applications. Users are responsible for validating serum suitability in their own experimental systems. The manufacturer assumes no liability for deviations in experimental results arising from improper handling.
ZJ26F0938975
危险品化学品经营许可证（带存储）